Insurance coverage for COPD cell therapy is inconsistent globally. US Medicare and commercial insurance do not reimburse. European insurance (Spain, Portugal, occasionally Germany) selectively covers for severe COPD (GOLD grade III–IV) when conventional treatment has been optimised and the patient meets strict functional disability criteria. Explicit pre-authorisation and pulmonology documentation are required. Most patients are responsible for out-of-pocket costs unless enrolled in sponsored trials.
COPD cell therapy costs €5,000–7,500 per protocol in specialised respiratory centres. Intravenous MSC infusion (€5,500–6,500) is standard. Inhaled exosome therapy (€4,500–5,500) is emerging and may be more cost-effective. Multiple infusions (2–4 over 6 months) increase total cost to €10,000–25,000. Concomitant conventional COPD management (medications, pulmonary rehabilitation) is mandatory and separately funded. Insurance coverage is rare; a few European countries (Spain, Portugal) selectively reimburse for severe COPD (GOLD grade III–IV) with significant disability and failed optimised conventional therapy.
Am I a candidate? → · COPD & Lung Disease: full overview → · COPD & Lung Disease cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung